RESULTS OF CLINICAL EVALUATION OF HYDRAZINE SULFATE

[VOPROSY ONKOLOGII 36:721-726, 1990]

V.A. Filov, L.A. Danova, M.L. Gershanovich, B.A. Ivin, N.P. Dementyeva, P.V. Beyvis, V.P. Ragaishene, I.V. Kasyanenko, A.I. Lisitsa, S.S. Mindlin and N.I. Kurganova

Abstract. This paper discusses results of a cooperative study of the effectiveness of hydrazine sulfate therapy in 740 patients with primary advanced, recurrent and metastic solid tumors and malignant lymphomas sho had failed all other treatment modalities. Both objective response and symptomatic effect wre assessed. Objective response was observed in neuroblastoma, recurrent desmoid, Hodgkin’s disease, lung cancer, fibrosarcoma and other tumors. Since hydrazine sulfate provided relief of a wide spectrum of cancer symptoms, it may be recommended for patients with end-stage cancer.

This page is designed and hosted by Next Generation Computer Systems, and is the property of the Syracuse Cancer Research Institute. © 1996, Syracuse Cancer Research Institute. All rights reserved.
Last modified on 04 June 1998 by webteam@ngen.com.